Vigilant Biosciences, Inc.
VigilantBIO develops technology to enable early detection of disease. Our initial product is an oral rinse screening kit for oral cancer.
Oral cancer has a higher mortality rate than cervical cancer and prostate cancer. This high mortality rate is due to late stage diagnosis at Stage III or IV. Our patented oral rinse screening kit can be readily used by frontline screeners such as dentists to enable the early detection of oral cancer. Our products are supported by two clinical trials, prototypes are under development, and the products will be ready for commercial sales in 2015.